The DOI matches its Crossref record; 60 of the 60 references it cites were found in a registry or an index.
Structural basis of PROTAC cooperative recognition for selective protein degradation
Open accessAbstract
Inducing macromolecular interactions with small molecules to activate cellular signaling is a challenging goal. PROTACs (proteolysis-targeting chimeras) are bifunctional molecules that recruit a target protein in proximity to an E3 ubiquitin ligase to trigger protein degradation. Structural elucidation of the key ternary ligase-PROTAC-target species and its impact on target degradation selectivity remain elusive. We solved the crystal structure of Brd4 degrader MZ1 in complex with human VHL and the Brd4 bromodomain (Brd4 BD2). The ligand folds into itself to allow formation of specific intermolecular interactions in the ternary complex. Isothermal titration calorimetry studies, supported by surface mutagenesis and proximity assays, are consistent with pronounced cooperative formation of ternary complexes with Brd4 BD2. Structure-based-designed compound AT1 exhibits highly selective depletion of Brd4 in cells. Our results elucidate how PROTAC-induced de novo contacts dictate preferential recruitment of a target protein into a stable and cooperative complex with an E3 ligase for selective degradation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“By contrast, the cooperativity of a bifunctional proximity inducer system is attributable to the ligand-induced protein–protein interface37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“In previous studies of bifunctional proximity inducers, a cooperativity term (represented by α) has been used to characterize the effects of protein–protein interaction in ternary complex formation36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“When plotted on a logarithmic scale, the MG dose-response curve has a familiar sigmoid shape (Fig. 7c), which is in stark contrast to the bell-shaped dose-response curve produced by the bifunctional proximity inducers36,37.”
From Defining molecular glues with a dual-nanobody cannabidiol sensor (2022) · cites this paper as [37]
In the citing paper
“Several mechanisms have been shown to contribute to this increase in selectivity. This includes steric incapability of some targets to form a productive ternary complex, or lack of a suitably positioned lysine residue for ubiquitination.62−69”
From Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence (2023) · cites this paper as [63]
In the citing paper
“It is widely believed that degraders uncouple efficacy from target occupancy (Gadd et al., 2017; Nowak et al., 2018; Olson et al., 2018; Roy et al., 2019).”
From Mapping the Degradable Kinome Provides a Resource for Expedited Degrader Development (2020) · cites this paper as Gadd et al., 2017
In the citing paper
“An essential step in targeted protein degradation is the drug-induced formation of a ternary complex10,43.”
From Functional E3 ligase hotspots and resistance mechanisms to small-molecule degraders (2023) · cites this paper as [10]
In the citing paper
“While there have been several published crystal structures of ternary complexes 35, 52, 54, there are not yet enough to allow for a thorough and rigorous evaluation of our method.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“The observation that many effective PROTACs exhibit cooperativity in assembling the components of the ternary complex 35, 52, 53 implies the presence of adventitious favorable interactions between the target protein and the E3 ligase in the ternary complex.”
From Rationalizing PROTAC-Mediated Ternary Complex Formation Using Rosetta (2021) · cites this paper as [52]
In the citing paper
“Cooperativity plays a role in the efficiency of the VHL–BRD4 degrader MZ1 (ref.129), but is dispensable for CRBN–BRD4 degraders130.”
From PROTAC targeted protein degraders: the past is prologue (2022) · cites this paper as [129]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
VMD: visual molecular dynamics
Humphrey, W., Dalke, A., & Schulten, K. (1996) · Journal of Molecular Graphics · doi:10.1016/0263-7855(96)00018-5 · Cited by 66,952
Features and development of Coot
Emsley, P., Lohkamp, B., Scott, W. G., & Cowtan, K. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910007493 · Cited by 29,915
Phaser crystallographic software
McCoy, A. J., Grosse-Kunstleve, R. W., Adams, P. D., Winn, M. D., Storoni, L. C., & Read, R. J. (2007) · Journal of Applied Crystallography · doi:10.1107/s0021889807021206 · Cited by 20,612
Scalable molecular dynamics with NAMD
Phillips, J. C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R. D., Kalé, L., & Schulten, K. (2005) · Journal of Computational Chemistry · doi:10.1002/jcc.20289 · Cited by 16,914
Kabsch, W. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909047337 · Cited by 16,463
MolProbity : all-atom structure validation for macromolecular crystallography
Chen, V. B., Arendall, W. B., Headd, J. J., Keedy, D. A., Immormino, R. M., Kapral, G. J., Murray, L. W., Richardson, J. S., & Richardson, D. C. (2010) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444909042073 · Cited by 14,115
Overview of the CCP 4 suite and current developments
Winn, M. D., Ballard, C. C., Cowtan, K. D., Dodson, E. J., Emsley, P., Evans, P. R., Keegan, R. M., Krissinel, E. B., Leslie, A. G. W., McCoy, A., et al. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444910045749 · Cited by 12,353
Inference of Macromolecular Assemblies from Crystalline State
Krissinel, E., & Henrick, K. (2007) · Journal of Molecular Biology · doi:10.1016/j.jmb.2007.05.022 · Cited by 10,007
CHARMM: The biomolecular simulation program
Brooks, B. R., Brooks, C. L., MacKerell, A. D., Nilsson, L., Petrella, R. J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009) · Journal of Computational Chemistry · doi:10.1002/jcc.21287 · Cited by 9,115
REFMAC 5 for the refinement of macromolecular crystal structures
Murshudov, G. N., Skubák, P., Lebedev, A. A., Pannu, N. S., Steiner, R. A., Nicholls, R. A., Winn, M., Long, F., & Vagin, A. A. (2011) · Acta Crystallographica Section D Biological Crystallography · doi:10.1107/s0907444911001314 · Cited by 8,415
Cited by
Sorted by citations
Items 301–400 of 1,001
Discovery of a Novel BCL-XL PROTAC Degrader with Enhanced BCL-2 Inhibition
Pal, P., Thummuri, D., Lv, D., Liu, X., Zhang, P., Hu, W., Poddar, S. K., Hua, N., Khan, S., Yuan, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00517 · Cited by 60
Thomas, J. E., Wang, M., Jiang, W., Wang, M., Wang, L., Wen, B., Sun, D., & Wang, S. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00492 · Cited by 60
Expanding the horizons of targeted protein degradation: A non-small molecule perspective
Huang, X., Wu, F., Ye, J., Wang, L., Wang, X., Li, X., & He, G. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.010 · Cited by 62
Wolter, M., de Vink, P. J., Neves, J. F., Srdanović, S., Higuchi, Y., Kato, N., Wilson, A. J., Landrieu, I., Brunsveld, L., & Ottmann, C. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c02151 · Cited by 60
Discovery of a dual WDR5 and Ikaros PROTAC degrader as an anti-cancer therapeutic
Li, D., Yu, X., Kottur, J., Gong, W., Zhang, Z., Storey, A. J., Tsai, Y., Uryu, H., Shen, Y., Byrum, S. D., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02340-8 · Cited by 61
Harnessing the cyclization strategy for new drug discovery
Tang, K., Wang, S., Gao, W., Song, Y., & Yu, B. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.09.022 · Cited by 59
Wang, C., Zheng, C., Wang, H., Shui, S., Jin, H., Liu, G., Xu, F., Liu, Z., Zhang, L., Sun, D., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.115072 · Cited by 59
High Accuracy Prediction of PROTAC Complex Structures
Ignatov, M., Jindal, A., Kotelnikov, S., Beglov, D., Posternak, G., Tang, X., Maisonneuve, P., Poda, G. I., Batey, R. A., Sicheri, F., et al. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c09387 · Cited by 59
Proteolysis targeting chimeras (PROTACs) for epigenetics research
Vogelmann, A., Robaa, D., Sippl, W., & Jung, M. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2020.01.010 · Cited by 59
Reversible Covalent Imine-Tethering for Selective Stabilization of 14-3-3 Hub Protein Interactions
Cossar, P. J., Wolter, M., Dijck, L. V., Valenti, D., Levy, L. M., Ottmann, C., & Brunsveld, L. (2021) · Journal of the American Chemical Society · doi:10.1021/jacs.1c03035 · Cited by 59
G4-PROTAC: targeted degradation of a G-quadruplex binding protein
Patil, K. M., Chin, D., Seah, H. L., Shi, Q., Lim, K. W., & Phan, A. T. (2021) · Chemical Communications · doi:10.1039/d1cc05025g · Cited by 58
Eron, S. J., Huang, H., Agafonov, R. V., Fitzgerald, M. E., Patel, J., Michael, R. E., Lee, T. D., Hart, A. A., Shaulsky, J., Nasveschuk, C. G., et al. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00376 · Cited by 57
Enriching Proteolysis Targeting Chimeras with a Second Modality: When Two Are Better Than One
Salerno, A., Seghetti, F., Caciolla, J., Uliassi, E., Testi, E., Guardigni, M., Roberti, M., Milelli, A., & Bolognesi, M. L. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00302 · Cited by 58
Recent Advances in PROTAC-Based Antiviral Strategies
Ahmad, H., Zia, B., Husain, H., & Husain, A. (2023) · Vaccines · doi:10.3390/vaccines11020270 · Cited by 57
Systematic Potency and Property Assessment of VHL Ligands and Implications on PROTAC Design
Krieger, J., Sorrell, F. J., Wegener, A. A., Leuthner, B., Machrouhi, F., Hecht, M., Leibrock, E.-M., Müller, J. E., Eisert, J., Hartung, I. V., et al. (2023) · ChemMedChem · doi:10.1002/cmdc.202200615 · Cited by 57
Applications and prospects of cryo-EM in drug discovery
Zhu, K., Yuan, C., Du, Y., Sun, K., Zhang, X., Vogel, H., Jia, X., Gao, Y., Zhang, Q., Wang, D., et al. (2023) · Military Medical Research · doi:10.1186/s40779-023-00446-y · Cited by 57
Current advances of small molecule E3 ligands for proteolysis-targeting chimeras design
Mi, D., Li, Y., Gu, H., Li, Y., & Chen, Y. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.115444 · Cited by 58
Ubiquitin–proteasome system as a target for anticancer treatment—an update
Kim, Y. J., Lee, Y., Shin, H. Y., Hwang, S., Park, J., & Song, E. J. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01455-0 · Cited by 57
3D based generative PROTAC linker design with reinforcement learning
Li, B., Ran, T., & Chen, H. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad323 · Cited by 57
Development and crystal structures of a potent second-generation dual degrader of BCL-2 and BCL-xL
Nayak, D., Lv, D., Yuan, Y., Zhang, P., Hu, W., Nayak, A., Ruben, E. A., Lv, Z., Sung, P., Hromas, R., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46922-4 · Cited by 61
Small molecule PROTACs in targeted therapy: An emerging strategy to induce protein degradation
Xi, M., Chen, Y., Yang, H., Xu, H., Du, K., Wu, C., Xu, Y., Deng, L., Luo, X., Yu, L., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.036 · Cited by 57
Molecular glues and induced proximity: An evolution of tools and discovery
Robinson, S. A., Co, J., & Banik, S. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.04.001 · Cited by 58
Drug design targeting active posttranslational modification protein isoforms
Meng, F., Liang, Z. T., Zhao, K., & Luo, C. (2020) · Medicinal Research Reviews · doi:10.1002/med.21774 · Cited by 56
Translational PK–PD for targeted protein degradation
Bartlett, D. W., & Gilbert, A. M. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00114d · Cited by 55
Targeted Protein Degradation by Chimeric Small Molecules, PROTACs and SNIPERs
Naito, M., Ohoka, N., Shibata, N., & Tsukumo, Y. (2019) · Frontiers in Chemistry · doi:10.3389/fchem.2019.00849 · Cited by 55
Luo, X., Archibeque, I., Dellamaggiore, K., Smither, K., Homann, O. R., Lipford, J. R., & Mohl, D. A. (2022) · iScience · doi:10.1016/j.isci.2022.103985 · Cited by 55
Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach
Chen, Q., Liu, C., Wang, W., Meng, X., Cheng, X., Li, X.-Y., Cai, L., Luo, L., He, X., Qu, H., et al. (2023) · ACS Chemical Biology · doi:10.1021/acschembio.2c00797 · Cited by 55
Zhou, Z., Zhou, G., Zhou, C., Fan, Z., Cui, R., Li, Y., Li, R., Gu, Y., Li, H., Ge, Z., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00075 · Cited by 56
Development of PROTAC Degrader Drugs for Cancer
Vetma, V., O’Connor, S., & Ciulli, A. (2024) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-061824-105806 · Cited by 55
Self-citationHDAC3 and HDAC8 PROTAC dual degrader reveals roles of histone acetylation in gene regulation
Xiao, Y., Hale, S. M., Awasthee, N., Meng, C., Zhang, X., Liu, Y., Ding, H., Huo, Z., Lv, D., Zhang, W., et al. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.07.010 · Cited by 54
Epigenetic drugs in cancer therapy: mechanisms, immune modulation, and therapeutic applications
Ma, C., Cheng, J., Gu, J. H., & Wang, Q. (2025) · Molecular Biomedicine · doi:10.1186/s43556-025-00373-5 · Cited by 56
Li, Z., Lin, Y., Song, H., Qin, X., Yu, Z., Zhang, Z., Dong, G., Li, X., Shi, X., Du, L., et al. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.014 · Cited by 54
A critical evaluation of the approaches to targeted protein degradation for drug discovery
Chopra, R., Sadok, A., & Collins, I. (2019) · Drug Discovery Today: Technologies · doi:10.1016/j.ddtec.2019.02.002 · Cited by 53
Marak, B. N., Dowarah, J., Khiangte, L., & Singh, V. P. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112571 · Cited by 53
Park, D. J., Izaguirre, J. A., Coffey, R., & Xu, H. (2022) · ACS Bio & Med Chem Au · doi:10.1021/acsbiomedchemau.2c00037 · Cited by 54
Plesniak, M. P., Taylor, E. K., Eisele, F., Kourra, C. M. B. K., Michaelides, I. N., Oram, A., Wernevik, J., Valencia, Z. S., Rowbottom, H., Mann, N., et al. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00314 · Cited by 52
Degraders upgraded: the rise of PROTACs in hematological malignancies
Casan, J. M. L., & Seymour, J. F. (2024) · Blood · doi:10.1182/blood.2023022993 · Cited by 53
Pharmacological difference between degrader and inhibitor against oncogenic BCR-ABL kinase
Shibata, N., Shimokawa, K., Nagai, K., Ohoka, N., Hattori, T., Miyamoto, N., Ujikawa, O., Sameshima, T., Nara, H., Cho, N., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-31913-5 · Cited by 52
Cooperativity basis for small-molecule stabilization of protein–protein interactions
de Vink, P. J., Andrei, S. A., Higuchi, Y., Ottmann, C., Milroy, L. ‐., & Brunsveld, L. (2019) · Chemical Science · doi:10.1039/c8sc05242e · Cited by 54
Applications of isothermal titration calorimetry in pure and applied research from 2016 to 2020
Falconer, R. J., Schuur, B., & Mittermaier, A. (2021) · Journal of Molecular Recognition · doi:10.1002/jmr.2901 · Cited by 52
PROTAC technology for the treatment of Alzheimer’s disease: advances and perspectives
Inuzuka, H., Liu, J., Wei, W., & Rezaeian, A.-H. (2022) · Acta Materia Medica · doi:10.15212/amm-2021-0001 · Cited by 54
Chen, H., Chen, F., Liu, N., Wang, X., & Gou, S. (2018) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2018.09.005 · Cited by 51
Zhang, W., Roy Burman, S. S., Chen, J., Donovan, K. A., Cao, Y., Shu, C., Zhang, B., Zeng, Z., Gu, S., Zhang, Y., et al. (2022) · Genomics, Proteomics & Bioinformatics · doi:10.1016/j.gpb.2022.11.008 · Cited by 51
Maity, P., Chatterjee, J., Patil, K. T., Arora, S., Katiyar, M. K., Kumar, M., Samarbakhsh, A., Joshi, G., Bhutani, P., Chugh, M., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01242 · Cited by 51
Lessons learned in linking PROTACs from discovery to the clinic
Pike, A., Lee, E. C. Y., Michaelides, I. N., Schade, M., Sharma, A., Scott, J. S., & Srivastava, A. (2025) · Nature Reviews Chemistry · doi:10.1038/s41570-025-00784-6 · Cited by 54
Triazol: A Privileged Scaffold for Proteolysis Targeting Chimeras
Xia, L., Ba, M.-Y., Liu, W., Cheng, W., Hu, C.-P., Zhao, Q., Yao, Y., Sun, M., & Duan, Y. (2019) · Future Medicinal Chemistry · doi:10.4155/fmc-2019-0159 · Cited by 51
Advancing Targeted Protein Degradation via Multiomics Profiling and Artificial Intelligence
Duran-Frigola, M., Cigler, M., & Winter, G. E. (2023) · Journal of the American Chemical Society · doi:10.1021/jacs.2c11098 · Cited by 50
Applications of Bacterial Degrons and Degraders — Toward Targeted Protein Degradation in Bacteria
Izert, M. A., Klimecka, M. M., & Górna, M. W. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.669762 · Cited by 50
Potential of E3 Ubiquitin Ligases in Cancer Immunity: Opportunities and Challenges
Ye, P., Chi, X., Cha, J., Luo, S., Yang, G., Yan, X., & Yang, W. (2021) · Cells · doi:10.3390/cells10123309 · Cited by 51
Silva, M. C., Nandi, G., Donovan, K. A., Cai, Q., Berry, B. C., Nowak, R. P., Fischer, E. S., Gray, N. S., Ferguson, F. M., & Haggarty, S. J. (2022) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2022.801179 · Cited by 51
Engineered platelets as targeted protein degraders and application to breast cancer models
Chen, Y., Pal, S., Li, W., Liu, F., Yuan, S., & Hu, Q. (2024) · Nature Biotechnology · doi:10.1038/s41587-024-02494-8 · Cited by 49
Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer
Wang, C., Wang, H., Zheng, C., Liu, Z., Gao, X., Xu, F., Niu, Y., Zhang, L., & Xu, P. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113386 · Cited by 49
Lucas, X., Molle, I. V., & Ciulli, A. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00842 · Cited by 46
Self-citationDevelopment of CDK4/6 Inhibitors: A Five Years Update
Ammazzalorso, A., Agamennone, M., Filippis, B. D., & Fantacuzzi, M. (2021) · Molecules · doi:10.3390/molecules26051488 · Cited by 48
Targeting CDK4/6 for Anticancer Therapy
Qi, J., & Ouyang, Z. (2022) · Biomedicines · doi:10.3390/biomedicines10030685 · Cited by 49
The impact of E3 ligase choice on PROTAC effectiveness in protein kinase degradation
Sobierajski, T., Małolepsza, J., Pichlak, M., Gendaszewska‐Darmach, E., & Błażewska, K. M. (2024) · Drug Discovery Today · doi:10.1016/j.drudis.2024.104032 · Cited by 48
Li, Z., Lim, S. L., Tao, Y., Li, X., Xie, Y., Yang, C., Zhang, Z., Jiang, Y., Zhang, X., Cao, X., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.574525 · Cited by 48
Target Validation Using PROTACs: Applying the Four Pillars Framework
Nowak, R. P., & Jones, L. H. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220979584 · Cited by 48
Design of a Cereblon construct for crystallographic and biophysical studies of protein degraders
Kroupova, A., Spiteri, V. A., Rutter, Z. J., Furihata, H., Darren, D., Ramachandran, S., Chakraborti, S., Haubrich, K., Pethe, J., Gonzales, D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52871-9 · Cited by 47
Self-citationWard, J. A., Perez‐Lopez, C., & Mayor‐Ruiz, C. (2023) · ChemBioChem · doi:10.1002/cbic.202300163 · Cited by 48
Proximity-inducing modalities: the past, present, and future
Singh, S., Tian, W., Severance, Z. C., Chaudhary, S. K., Anokhina, V. S., Mondal, B., Pergu, R., Singh, P. R., Dhawa, U., Singha, S., et al. (2023) · Chemical Society Reviews · doi:10.1039/d2cs00943a · Cited by 47
The cyclimids: Degron-inspired cereblon binders for targeted protein degradation
Ichikawa, S., Payne, N. C., Xu, W., Chang, C., Vallavoju, N., Frome, S., Flaxman, H. A., Mazitschek, R., & Woo, C. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.01.003 · Cited by 49
The emerging roles of non-canonical ubiquitination in proteostasis and beyond
Akizuki, Y., Kaypee, S., Ohtake, F., & Ikeda, F. (2024) · The Journal of Cell Biology · doi:10.1083/jcb.202311171 · Cited by 47
Emerging strategies for prospective discovery of molecular glue degraders
Wang, B., Cao, S., & Zheng, N. (2024) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2024.102811 · Cited by 47
Optimization of a “bump-and-hole” approach to allele-selective BET bromodomain inhibition
Runcie, A. C., Zengerle, M., Chan, K.-H., Testa, A., van Beurden, L., Baud, M. G. J., Epemolu, O., Ellis, L. C. J., Read, K. D., Coulthard, V., et al. (2018) · Chemical Science · doi:10.1039/c7sc02536j · Cited by 47
Self-citationBRD4 Regulates Metastatic Potential of Castration-Resistant Prostate Cancer through AHNAK
Shafran, J. S., Andrieu, G. P., Győrffy, B., & Denis, G. V. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-1279 · Cited by 47
PROTACs bearing piperazine-containing linkers: what effect on their protonation state?
Desantis, J., Mammoli, A., Eleuteri, M., Coletti, A., Croci, F., Macchiarulo, A., & Goracci, L. (2022) · RSC Advances · doi:10.1039/d2ra03761k · Cited by 46
Beyond canonical PROTAC: biological targeted protein degradation (bioTPD)
Wang, H., Zhou, R., Xu, F., Yang, K., Zheng, L., Zhao, P., Shi, G., Dai, L., Xu, C., Yu, L., et al. (2023) · Biomaterials Research · doi:10.1186/s40824-023-00385-8 · Cited by 48
Proteolysis‐Targeting Chimera (PROTAC): Current Applications and Future Directions
Fan, G., Chen, S., Zhang, Q., Yu, N., Shen, Z., Liu, Z., Guo, W., Tang, Z., Yang, J., & Liu, M. (2025) · MedComm · doi:10.1002/mco2.70401 · Cited by 48
Development of a PDEδ‐Targeting PROTACs that Impair Lipid Metabolism
Winzker, M., Friese, A., Koch, U., Janning, P., Ziegler, S., & Waldmann, H. (2019) · Angewandte Chemie International Edition · doi:10.1002/anie.201913904 · Cited by 46
Identification of probe-quality degraders for Poly(ADP-ribose) polymerase-1 (PARP-1)
Zhang, Z., Chang, X., Zhang, C., Zeng, S., Liang, M., Ma, Z., Wang, Z., Huang, W., & Shen, Z. (2020) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2020.1804382 · Cited by 46
Riching, K. M., Schwinn, M. K., Vasta, J. D., Robers, M. B., Machleidt, T., Urh, M., & Daniels, D. L. (2020) · SLAS DISCOVERY · doi:10.1177/2472555220973602 · Cited by 46
Hati, S., Zallocchi, M., Hazlitt, R. A., Li, Y., Vijayakumar, S., Min, J., Ranković, Z., Lovas, S., & Zuo, J. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113849 · Cited by 46
Zhou, C., Fan, Z., Gu, Y., Ge, Z., Tao, Z., Cui, R., Li, Y., Zhou, G., Huo, R., Gao, M., et al. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01622 · Cited by 45
Darwish, S., Ghazy, E., Heimburg, T., Herp, D., Zeyen, P., Salem-Altintas, R., Ridinger, J., Schmidtkunz, K., Robaa, D., Erdmann, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147535 · Cited by 45
cIAP1-based degraders induce degradation via branched ubiquitin architectures
Akizuki, Y., Morita, M., Mori, Y., Kaiho-Soma, A., Dixit, S., Endo, A., Shimogawa, M., Hayashi, G., Naito, M., Okamoto, A., et al. (2022) · Nature Chemical Biology · doi:10.1038/s41589-022-01178-1 · Cited by 46
Degraders in epigenetic therapy: PROTACs and beyond
Dai, X., Ji, S., Fu, M., Liu, G.-Z., Liu, H., Wang, S., Shen, L., Wang, N., Herdewijn, P. A., Zheng, Y., et al. (2024) · Theranostics · doi:10.7150/thno.92526 · Cited by 45
Mechanism of millisecond Lys48-linked poly-ubiquitin chain formation by cullin-RING ligases
Liwocha, J., Li, J., Purser, N., Rattanasopa, C., Maiwald, S. A., Krist, D. T., Scott, D. C., Steigenberger, B. A., Prabu, J. R., Schulman, B. A., et al. (2024) · Nature Structural & Molecular Biology · doi:10.1038/s41594-023-01206-1 · Cited by 47
Proteolysis Targeting Chimera Degraders of the METTL3–14 m 6 A-RNA Methyltransferase
Errani, F., Invernizzi, A., Herok, M., Bochenkova, E., Stamm, F., Corbeski, I., Romanucci, V., Fabio, G. D., Zálešák, F., & Caflisch, A. (2024) · JACS Au · doi:10.1021/jacsau.4c00040 · Cited by 46
Selectivity through Targeted Protein Degradation (TPD)
Gopalsamy, A. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00397 · Cited by 45
Homobivalent, Trivalent, and Covalent PROTACs: Emerging Strategies for Protein Degradation
Yan, J., Li, T., Miao, Z., Wang, P., Sheng, C., & Zhuang, C. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00728 · Cited by 46
Discovery of a Selective and Orally Bioavailable FGFR2 Degrader for Treating Gastric Cancer
Ma, L., Li, Y., Luo, R., Wang, Y., Cao, J., Fu, W., Qian, B., Zheng, L., Tang, L., Lv, X., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c00150 · Cited by 44
Cullin-RING ligases employ geometrically optimized catalytic partners for substrate targeting
Li, J., Purser, N., Liwocha, J., Scott, D. C., Byers, H. A., Steigenberger, B. A., Hill, S., Tripathi‐Giesgen, I., Hinkle, T. B., Hansen, F. M., et al. (2024) · Molecular Cell · doi:10.1016/j.molcel.2024.01.022 · Cited by 47
Radioactive ADME Demonstrates ARV-110’s High Druggability Despite Low Oral Bioavailability
He, Y., Zheng, Y., Zhu, C., Peng, L., Yu, J., Tang, C., Chen, H., & Diao, X. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01104 · Cited by 45
Decoy-PROTAC for specific degradation of “Undruggable” STAT3 transcription factor
Li, S., Wang, X., Huang, J., Cao, X., Liu, Y., Bai, S., Zeng, T., Chen, Q., Li, C., Lü, C., et al. (2025) · Cell Death and Disease · doi:10.1038/s41419-025-07535-x · Cited by 44
Targeted protein degradation mechanisms
Zhang, Y., Loh, C., Chen, J., & Mainolfi, N. (2019) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2019.01.001 · Cited by 44
Grohmann, C., Magtoto, C. M., Walker, J. R., Chua, N. K., Gabrielyan, A., Hall, M., Cobbold, S. A., Mieruszynski, S., Brzozowski, M., Simpson, D. S., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-29670-1 · Cited by 43
Self-citationTargeting bromodomain-containing proteins: research advances of drug discovery
Pan, Z., Zhao, Y., Wang, X., Xie, X., Liu, M., Zhang, K., Wang, L., Bai, D., Foster, L. J., Shu, R., et al. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00127-1 · Cited by 43
Post-translational Modification of PD-1: Potential Targets for Cancer Immunotherapy
Lee, T.-A., Tsai, E.-Y., Liu, S.-H., Hung, S.-D. H., Chang, S., Chao, C.-H., Lai, Y., Yamaguchi, H., & Li, C. (2024) · Cancer Research · doi:10.1158/0008-5472.can-23-2664 · Cited by 43
Next steps for targeted protein degradation
Krone, M. W., & Crews, C. M. (2024) · Cell chemical biology · doi:10.1016/j.chembiol.2024.10.004 · Cited by 43
PROTACs: New method to degrade transcription regulating proteins
Hu, B.-C., Zhou, Y., Sun, D., Yang, Y., Liu, Y., Li, X., Li, H., & Chen, L. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112698 · Cited by 43
Identification and selectivity profiling of small-molecule degraders via multi-omics approaches
Scholes, N. S., Mayor‐Ruiz, C., & Winter, G. E. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.03.007 · Cited by 44
Kinase-targeting small-molecule inhibitors and emerging bifunctional molecules
Goebel, G. L., Qiu, X., & Wu, P. (2022) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2022.04.006 · Cited by 44
Click Chemistry and Targeted Degradation: A Winning Combination for Medicinal Chemists?
Pasieka, A., Diamanti, E., Uliassi, E., & Bolognesi, M. L. (2023) · ChemMedChem · doi:10.1002/cmdc.202300422 · Cited by 42
Radiation responsive PROTAC nanoparticles for tumor-specific proteolysis enhanced radiotherapy
Xu, M., Yun, Y., Li, C., Ruan, Y., Muraoka, O., Xie, W., & Sun, X. (2024) · Journal of Materials Chemistry B · doi:10.1039/d3tb03046f · Cited by 42
Yan, K., Nie, Y., Wang, J., Yin, G., Liu, Q., Hu, H., Sun, X., & Chen, X. (2024) · Advanced Science · doi:10.1002/advs.202400594 · Cited by 42
Setia, N., Almuqdadi, H. T. A., & Abid, M. (2023) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2023.116041 · Cited by 42
Desantis, J., Bazzacco, A., Eleuteri, M., Tuci, S., Bianconi, E., Macchiarulo, A., Mercorelli, B., Loregian, A., & Goracci, L. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116202 · Cited by 41
Benchmarking Methods for PROTAC Ternary Complex Structure Prediction
Rovers, E., & Schapira, M. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.4c00426 · Cited by 41
Ren, C., Sun, N., Liu, H., Kong, Y., Sun, R., Qiu, X., Chen, J., Li, Y., Zhang, J., Zhou, Y., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00373 · Cited by 41
Metadata
- Authors
- Gadd, M. S., Testa, A., Lucas, X., Chan, K.-H., Chen, W., Lamont, D. J., Zengerle, M., & Ciulli, A.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Ciulli, Alessio
- Venue
- Nature Chemical Biology
- Published
- 2017-03-13
- Volume
- 13
- Issue
- 5
- Pages
- 514-521
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- PMC
- PMC5392356
- OpenAlex
- W2597078857
- Cited by
- 1,242
- References
- 60
- Citations by year
- 2026: 173 · 2025: 173 · 2024: 176 · 2023: 159 · 2022: 138 · 2021: 129 · 2020: 133 · 2019: 86 · 2018: 46 · 2017: 26
- FWCI
- 33.34
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Chemical Biology (publishedVersion)
- PubMed (publishedVersion)
- Lancaster EPrints (Lancaster University) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Discovery Research Portal (University of Dundee) (submittedVersion, other-oa)
- Funders
- Wellcome Trust (100476, 094090/Z/10/Z, 094090, 100476/Z/12/Z)
- Diamond Light Source (MX10071)
- European Commission (H2020-MSCA-IF-2014, H2020- MSCA-IF-2015, H2020, 655516, H2020‐MSCA‐IF, H2020-MSCA)
- Directorate for Biological Sciences
- Horizon 2020 Framework Programme (H2020‐MSCAIF‐2014, H2020-MSCA, MSCA-IF-2014, H2020-MSCA-IF-2015)
- Medical Research Council
- Biotechnology and Biological Sciences Research Council (BB/J001201/1, BB/J001201/2)
- H2020 Marie Skłodowska-Curie Actions (H2020-MSCA-IF-2014, H2020-MSCA-IF-2014-655516, H2020, 655516, H2020-MSCA-IF, H2020-MSCA-IF-2015, H2020-MSCA, 806323, H2020-MSCA-IF-2015-806323)
- FP7 Ideas: European Research Council (311460)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Ubiquitin and proteasome pathways
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- PROTACs, BRD4, VHL E3 ubiquitin ligase, bromodomain, selective protein degradation, crystal structure, ternary complex, structure-based drug design, ubiquitination
- MeSH terms
- Elongin, Bromodomain Containing Proteins, Amino Acid Sequence, Dipeptides, Heterocyclic Compounds, 3-Ring, Humans, Models, Molecular, Nuclear Proteins, Protein Binding, Protein Conformation, Structure-Activity Relationship, Thermodynamics, Transcription Factors, Crystallography, X-Ray, Cell Cycle Proteins, Ubiquitin-Protein Ligases, Multiprotein Complexes, Von Hippel-Lindau Tumor Suppressor Protein, Small Molecule Libraries, Proteolysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
